Inovio Pharmaceuticals Inc. closed 86.44% short of its 52-week high of $14.75, which the company achieved on April 1st.

Inovio Pharmaceuticals (NASDAQ:INO) just reported results for the fourth quarter of 2023. Inovio Pharmaceuticals reported earnings per share of -$1.10. This was above the analyst estimate for EPS ...

Shares of Inovio Pharmaceuticals pulled back by 5.3% during Wednesday's session. The decline may be attributed to profit-taking, as investors assess renewed focus on respiratory illnesses. Inovio ...

Shares of Inovio Pharmaceuticals Inc. INO slid 4.78% to $1.99 Monday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ Composite Index COMP falling 1.20% ...

S hares of Inovio Pharmaceuticals (INO) have gained 57.3% over the past four weeks to close the last trading session at $9.03, but there could still be a solid upside left in the stock if short ...

The company's lead product candidate, INO-4800, a DNA-based COVID-19 vaccine ... shares,' which allows you to own portions of stock without buying an entire share. For example, some stock ...

Its product pipeline includes VGX-3100, INO-3107, INO-5410, INO-4800, and PENNVAX-GP. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting ...

TORONTO, December 13, 2024--Inovalis Real Estate Investment Trust (the "REIT") (TSX: INO.UN) announced today that its Board of Trustees has declared a special distribution of $0.225 per Unit.

Nasdaq provides an interactive stock information chart to view history. Downloadable stock history data table is also accessible by clicking on Data Table on the navigation tool bar. If you have ...

TORONTO, December 13, 2024--Inovalis Real Estate Investment Trust (the "REIT") (TSX: INO.UN) announced today that its Board of Trustees has declared a special distribution of $0.225 per Unit. The ...